{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:51:11Z","timestamp":1781067071800,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.chest.2025.12.055","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:07:23Z","timestamp":1772557643000},"page":"1536-1550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients With COPD in China (PACER-II)"],"prefix":"10.1016","volume":"169","author":[{"given":"Li-Xiu","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4422-3674","authenticated-orcid":false,"given":"Zu-Ke","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa-Ming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Qin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun-Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Feng","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Qin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Zhong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran-Ran","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Bin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ju","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Guo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zu-Ke","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa-Ming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Qin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun-Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Feng","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Qin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Zhong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran-Ran","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Bin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ju","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Qian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Xia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Ping","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Sheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Li-Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.chest.2025.12.055_bib2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-2600(21)00511-7","article-title":"Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis","volume":"10","author":"Adeloye","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.chest.2025.12.055_bib3","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jama.2019.0131","article-title":"Diagnosis and outpatient management of chronic obstructive pulmonary disease: a review","volume":"321","author":"Riley","year":"2019","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.chest.2025.12.055_bib4","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S2213-2600(19)30190-0","article-title":"Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial","volume":"7","author":"Pascoe","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.chest.2025.12.055_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01219-2018","article-title":"Inhaled corticosteroids in COPD: friend or foe?","volume":"52","author":"Agusti","year":"2018","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.chest.2025.12.055_bib6","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrm911","article-title":"Cyclic nucleotide research\u2014still expanding after half a century","volume":"3","author":"Beavo","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.chest.2025.12.055_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1164\/rccm.201301-0021PP","article-title":"Phosphodiesterase-4 inhibitor therapy for lung diseases","volume":"188","author":"Begh\u00e8","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2025.12.055_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bcpt.12209","article-title":"Dual PDE3\/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases","volume":"114","author":"Abbott-Banner","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"16","key":"10.1016\/j.chest.2025.12.055_bib9","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s40265-021-01616-9","article-title":"Inhaled phosphodiesterase inhibitors for the treatment of chronic obstructive pulmonary disease","volume":"81","author":"Singh","year":"2021","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.chest.2025.12.055_bib10","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1476-5381.2009.00170.x","article-title":"Dual PDE3\/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease","volume":"157","author":"Banner","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"9971","key":"10.1016\/j.chest.2025.12.055_bib11","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(14)62410-7","article-title":"Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial","volume":"385","author":"Martinez","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.chest.2025.12.055_bib12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1183\/09031936.00178710","article-title":"Roflumilast with long-acting \u03b22-agonists for COPD: influence of exacerbation history","volume":"38","author":"Bateman","year":"2011","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2025.12.055_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12931-020-1307-4","article-title":"A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD","volume":"21","author":"Singh","year":"2020","journal-title":"Respir Res"},{"issue":"9","key":"10.1016\/j.chest.2025.12.055_bib14","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2213-2600(13)70187-5","article-title":"Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials","volume":"1","author":"Franciosi","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.chest.2025.12.055_bib15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","article-title":"Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE Trials)","volume":"208","author":"Anzueto","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2025.12.055_bib16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.chest.2024.07.168","article-title":"Effect of dual phosphodiesterase 3 and 4 inhibitor ensifentrine on exacerbation rate and risk in patients with moderate to severe COPD","volume":"167","author":"Sciurba","year":"2025","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.chest.2025.12.055_bib17","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s40265-025-02213-w","article-title":"Ensifentrine plus a long-acting muscarinic antagonist in COPD: a trifunctional dual bronchodilation perspective","volume":"85","author":"Cazzola","year":"2025","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.chest.2025.12.055_bib18","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.2217\/imt-2023-0136","article-title":"What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials","volume":"15","author":"Cazzola","year":"2023","journal-title":"Immunotherapy"},{"issue":"4","key":"10.1016\/j.chest.2025.12.055_bib21","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1164\/ajrccm.158.4.9802091","article-title":"Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease","volume":"158","author":"Hajiro","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2025.12.055_bib22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"issue":"16","key":"10.1016\/j.chest.2025.12.055_bib23","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2147\/COPD.S263025","article-title":"Symptom improvement following treatment with the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in patients with moderate to severe COPD\u2014a detailed analysis","volume":"15","author":"Watz","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"10.1016\/j.chest.2025.12.055_bib24","first-page":"124","article-title":"Responder analyses for treatment effects in COPD using the St George\u2019s Respiratory Questionnaire","volume":"4","author":"Jones","year":"2017","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"suppl B","key":"10.1016\/j.chest.2025.12.055_bib26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0954-6111(06)80166-6","article-title":"The St George\u2019s Respiratory Questionnaire","volume":"85","author":"Jones","year":"1991","journal-title":"Respir Med"},{"key":"10.1016\/j.chest.2025.12.055_bib27","article-title":"Late breaking abstract\u2014a dose-ranging study of the inhaled dual pde3\/4 inhibitor TQC3721 in COPD patients","volume":"64","author":"Luo","year":"2024","journal-title":"Eur Respir J"},{"issue":"22","key":"10.1016\/j.chest.2025.12.055_bib28","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2147\/COPD.S307160","article-title":"A dose-ranging study of the novel inhaled dual PDE 3 and 4 inhibitor ensifentrine in patients with COPD receiving maintenance tiotropium therapy","volume":"16","author":"Ferguson","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"10.1016\/j.chest.2025.12.055_bib29","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chest.2016.11.028","article-title":"Efficacy and safety of glycopyrrolate\/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients With COPD","volume":"151","author":"Martinez","year":"2017","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2025.12.055_bib30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","article-title":"FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease","volume":"196","author":"Lipson","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.chest.2025.12.055_bib32","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/cells14090659","article-title":"Advancing obstructive airway disease treatment: dual PDE3\/4 inhibition as a therapeutic strategy","volume":"14","author":"Sherpa","year":"2025","journal-title":"Cells"},{"issue":"14","key":"10.1016\/j.chest.2025.12.055_bib33","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s40265-015-0463-1","article-title":"Roflumilast: a review in COPD","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.chest.2025.12.055_bib34","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1124\/jpet.105.099192","volume":"318","author":"Boswell-Smith","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"23","key":"10.1016\/j.chest.2025.12.055_bib35","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.chest.2025.12.055_bib36","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1183\/09031936.00124013","article-title":"Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study","volume":"43","author":"Mahler","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2025.12.055_bib37","first-page":"PA3002","article-title":"Safety, tolerability and pharmacokinetics of the phosphodiesterase 3\/4 (PDE3\/4) inhibitor TQC3721 suspension for inhalation in healthy adult subjects","volume":"64","author":"Luo","year":"2024","journal-title":"Eur Respir J"},{"issue":"9691","key":"10.1016\/j.chest.2025.12.055_bib38","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","article-title":"Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials","volume":"374","author":"Fabbri","year":"2009","journal-title":"Lancet"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236922600262X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236922600262X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:25:06Z","timestamp":1781018706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001236922600262X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S001236922600262X"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2025.12.055","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients With COPD in China (PACER-II)","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2025.12.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2026.01.023","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Chest Physicians. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}